TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15180172
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (free combinations of decongestant nose drops, mucolytics, analgesics and antibiotics)
Study: 15180172
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment with Otovowen
Study: 9570261
Drug: Omeprazole treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole treatment strategy (10 mg stepping up to 20 mg and 40 mg as required)
Study: 9570261
Drug: Antacid-alginate/ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid-alginate/ranitidine treatment strategy (10 mL q.d.s. stepping up to ranitidine 150 mg b.d. and 150 mg q.d.s. as required)
Study: 28659128
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus minimally invasive esophagectomy (MIE)
Study: 28659128
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus MIE
Study: 26125194
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) using fentanyl
Study: 16771939
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (250 mg)
Study: 14607452
Drug: TEE-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEE-guided treatment
Study: 10997674
Drug: No Parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Parenteral Nutrition (no PN)
Study: 19807
Drug: Naloxone 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 1.2 mg
Study: 30290769
Drug: Antihelminthic drugs
Normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihelminthic drugs
Study: 12505955
Drug: Jet with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet with 0.5 mL of lidocaine 1%
Study: 12505955
Drug: Jet with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet with 0.5 mL of lidocaine 2%
Study: 12505955
Drug: Jet with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet with 0.5 mL of saline
Study: 7751490
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support treatment
Study: 7751490
Drug: Self-control treatment
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-control treatment
Study: 322546
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 20 mg
Study: 322546
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 5 mg
Study: 322546
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 10 mg
Study: 25972490
Drug: THC 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 1.5 mg three times daily for 3 weeks
Study: 25972490
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 3 weeks
Study: 25752889
Drug: THC 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 1.5 mg
Study: 16408462
Drug: Antihyperglycemic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihyperglycemic agent treatment
Study: 9739438
Drug: 5‐FU 425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 425 mg/m2 given by bolus injection on days 1‐5 plus intravenous (i.v.) LV 20 mg/m2 every four to five weeks
Study: 9739438
Drug: 5‐FU 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 3.5 g/m2/week in a 48‐hour continuous infusion
Study: 7994260
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) administration during and after autologous bone marrow transplantation (BMT)
Study: 2920496
Drug: Levodopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (250 mg) with Ferrous sulfate (325 mg)
Study: 2920496
Drug: Levodopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (250 mg) without Ferrous sulfate (325 mg)
Study: 25065293
Drug: FEC-D chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-D chemotherapy
Study: 25065293
Drug: Standard anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anthracycline-based chemotherapy
Study: 16579083
Drug: No. 2
Normalized name: K-Phos No. 2
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No. 2 Qu Feng Shi Ling capsules and Fenbid
Study: 16579083
Drug: Lei Gong
Normalized name: mAb Hu3S193 - Anti-LeY
DrugBank: hu3S193 (DB17213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lei Gong Teng Tablets and Fenbid
Study: 7655378
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (4800-6000 mg/m2) and carboplatin (1200-1800 mg/m2) followed by autologous bone marrow or peripheral blood stem cell infusion
Study: 7655378
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide and carboplatin regimen
Study: 23564922
Drug: Glucagon-like peptide
Normalized name: Glucagon-like peptide 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide 1 (GLP-1) infusion
Study: 21864370
Drug: PEPS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEPS therapy plus treatment as usual (TAU)
Study: 21864370
Drug: PEPS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEPS therapy plus TAU
Study: 20046538
Drug: Screening, brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening, brief intervention and referral to treatment (SBIRT)
Study: 17084787
Drug: Cognitive‐Behavioral Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Coping Skills Therapy
Study: 15605326
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without exercise program (control group)
Study: 11287029
Drug: DMPA+E(2)C injection
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA+E(2)C injection on day 7 of the menstrual cycle (delayed-injection group, n = 117)
Study: 11287029
Drug: DMPA+E(2)C injection
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMPA+E(2)C injection on day 5 of the menstrual cycle (control group, n = 41)
Study: 9311402
Drug: Hypnosis (audio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (audio tape daily 4-6 days prior to surgery)
Study: 8455803
Drug: Marine fish-oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine fish-oil supplements rich in n-3 fatty acids
Study: 8455803
Drug: Marine fish-oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine fish-oil supplements
Study: 25739829
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²/week for 4 weeks) with glucocorticoids and two intravenous cyclophosphamide pulses
Study: 25739829
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide for 3-6 months followed by azathioprine with glucocorticoids (Control group)
Study: 22706617
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal patch (5 μg/h)
Study: 22167031
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (10 mg in 20 ml of fruit juice)
Study: 22167031
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml of fruit juice)
Study: 10901839
Drug: Clobazam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (30 mg daily)
Study: 10901839
Drug: Lorazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3 mg daily)
Study: 10901839
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg daily)
Study: 1511768
Drug: Medical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical intervention (colposcopy examination or outpatient ablative treatment)
Study: 6140167
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-AS) 0.5 g suppositories
Study: 6140167
Drug: Sulphasalazine (SZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine (SZ) 1 g tid (equivalent to 5-AS 1.14 g/day)
Study: 6140167
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release form of 5-AS
Study: 16923481
Drug: Active patch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active patch (GTN)
Study: 15504999
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy (handheld infrared skin thermometer, measuring temperatures on the sole of the foot in the morning and evening)
Study: 15504999
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (therapeutic footwear, diabetic foot education, regular foot evaluation by a podiatrist)
Study: 12243704
Drug: Hydrocolloid dressing
Normalized name: hydrocolloid dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid dressing (HCD) over clobetasol propionate 0.05% lotion once a week
Study: 12243704
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate ointment used unoccluded twice a day
Study: 8327414
Drug: Aerosol inhaler
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inhaler (active bronchodilator or placebo)
Study: 8327414
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum as an adjunct to the behavioral program
Study: 19374071
Drug: African potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: African potato (AP) decoction administered daily from day 16 to day 30
Study: 12719963
Drug: Nutritionally-sourced tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutritionally-sourced tryptophan (1.8 g)
Study: 10320169
Drug: Midazolam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.04 mg/kg) IV
Study: 29668535
Drug: Monthly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly high-dose oral cholecalciferol over 2 years
Study: 18330460
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT), 8 sessions
Study: 15839956
Drug: Paclitaxel-platinum combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-platinum combination therapy
Study: 15839956
Drug: Conventional platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional platinum-based therapy
Study: 12209102
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with HDM-impermeable encasings for mattresses, pillows, and duvets for 12 months.
Study: 12209102
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with cotton encasings for mattresses, pillows, and duvets for 12 months.
Study: 10496190
Drug: Enalapril therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril therapy in white patients
Study: 10496190
Drug: Enalapril therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril therapy in white patients with a history of hypertension
Study: 9191512
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg
Study: 3030387
Drug: Perindopril 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 16 mg
Study: 6344038
Drug: Zomepirac sodium
Normalized name: zomepirac sodium
DrugBank: Zomepirac (DB04828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomepirac sodium 100 mg
Study: 6587296
Drug: Fenoprofen calcium
Normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoprofen calcium 200 mg
Study: 30882751
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 × 200 mg elemental iron (SINGLE)
Study: 30882751
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose of 2 × 100 mg elemental iron (SPLIT)
Study: 22712470
Drug: Tretinoin microsphere
Normalized name: tretinoin microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin microsphere gel 0.04% pump
Study: 17636093
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise with bright light treatment
Study: 17636093
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise without bright light treatment
Study: 16118756
Drug: Hip head-conserving
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip head-conserving therapy with two cranial screws and a three-point-supported screw at Adam's arc
Study: 7567130
Drug: Ceftriaxone 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1,000 mg intravenously 30 min before anesthesia
Study: 7567130
Drug: Ceftriaxone 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1,000 mg intravenously before anesthesia and a second 1,000 mg dose at the initiation of cardiopulmonary bypass
Study: 7567130
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (1,000 mg and 2,000 mg regimens)
Study: 2127604
Drug: hMG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG treatment with short-term GnRH agonist (Buserelin)
Study: 2127604
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with hMG alone
Study: 2127604
Drug: hMG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG treatment started shortly after LH rise caused by GnRH agonist
Study: 2127604
Drug: hMG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG treatment commenced when hypogonadotropic state achieved after long treatment of Buserelin
Study: 2127604
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (hMG with and without GnRH agonist)
Study: 21849007
Drug: Sitagliptin (SITA)
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin (SITA) 100 mg qd
Study: 31802616
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 850 mg bid
Study: 31802616
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Sitagliptin (MET+SITA) 50 + 850 mg bid
Study: 31471037
Drug: Losartan (LT)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (LT) 50 mg
Study: 29948456
Drug: Combined 660-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 660- and 808-nm wavelengths low-level laser therapy (LLLT) (300 J/cm2, 9 J of total energy, 100 mW, spot size 3 mm2), performed twice a week.
Study: 29948456
Drug: 660-nm wavelength
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 660-nm wavelength low-level laser therapy (LLLT) (300 J/cm2, 9 J of total energy, 100 mW, spot size 3 mm2), performed twice a week.
Study: 25187257
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (vitamin C) 10 mg/kg/day and α-tocopherol (vitamin E) 10 mg/kg/day
Study: 22342027
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral self-help program (SHP) combined with pharmacotherapy
Study: 22342027
Drug: Pharmacotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy alone (control)
Study: 20228402
Drug: Nateglinide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (up to 60 mg three times daily)
Study: 15797672
Drug: Calcium pyruvate
Normalized name: Calcium pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium pyruvate (PYR) 5 g twice daily for 30 days
Study: 9927844
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (t-PA)
Study: 2669554
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 400 micrograms
Study: 2669554
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 1000 micrograms
Study: 2669554
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (BUD) 400 micrograms
Study: 2669554
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (BUD) 800 micrograms
Study: 365774
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose subunit vaccine (2100 IU)
Study: 947849
Drug: Whole virus
Normalized name: rabies, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole virus vaccine (2100 IU)
Study: 365774
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose subunit vaccine (700 IU)
Study: 365774
Drug: Split virus
Normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split virus adjuvant vaccine (800 IU with AI(OH)3)
Study: 30580896
Drug: Stereoscopic 3D
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereoscopic 3D immersive video exposure-based treatment (six 5-minute exposures)
Study: 16455419
Drug: Ultrasound contrast
Normalized name: ULTRASOUND CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound contrast agent (UCA) Optison
Study: 16455419
Drug: Contrast agents
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agents (Optison, Sonovue, Sonazoid)
Study: 15762255
Drug: Other cemented
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other cemented implants
Study: 8214276
Drug: mefloquine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mefloquine treatment
Study: 3593451
Drug: Terguride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terguride (2 X 0.2 mg/d per os)
Study: 24655769
Drug: Group-based counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based counselling intervention for depression adapted from Interpersonal Therapy (IPT)
Study: 19730952
Drug: Single-dose Stretta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose Stretta (Group A)
Study: 19730952
Drug: Double-dose Stretta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose Stretta (Group C)
Study: 9203723
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) administered at 2 and 3 months of age followed by doses of both IPV and oral poliovirus vaccine (OPV) at 4 and 9 months of age
Study: 8291408
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg 3 times daily for 2 weeks
Study: 24839241
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5mg yearly infusion
Study: 22153327
Drug: Contemporary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contemporary treatment or task-specific training
Study: 20505273
Drug: Orbital lesion
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital lesion and oral cavity lesion
Study: 20505273
Drug: Bilateral orbital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral orbital lesions, buccal, rectum, and stomach lesions
Study: 17490954
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) at a dose of 3.2 g/d
Study: 16308498
Drug: CC-guided PV
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-guided PV isolation
Study: 25361685
Drug: Self-reported medication
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medication non-adherence
Study: 23183356
Drug: Tyrothricin 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrothricin 0.1% gel
Study: 21450978
Drug: AS03(A)‐adjuvanted H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)‐adjuvanted H1N1 vaccine containing 3.75 μg hemagglutinin (HA)
Study: 21450978
Drug: Nonadjuvanted H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted H1N1 vaccine containing 15 μg HA
Study: 21450978
Drug: Nonadjuvanted H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted H1N1 vaccine containing 3.75 μg HA
Study: 17892986
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (EPO) for 4 months followed by maintenance for another 8 months, with oral iron throughout 12 months.
Study: 17892986
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received saline as placebo and oral iron throughout 12 months.